Suppliers and packagers for dapsone

dapsone

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Alembic	DAPSONE	dapsone	GEL;TOPICAL	215718	ANDA	Alembic Pharmaceuticals Limited	46708-663-30	1 BOTTLE, PUMP in 1 CARTON (46708-663-30) / 30 g in 1 BOTTLE, PUMP	2023-10-30
Alembic	DAPSONE	dapsone	GEL;TOPICAL	215718	ANDA	Alembic Pharmaceuticals Limited	46708-663-60	1 BOTTLE, PUMP in 1 CARTON (46708-663-60) / 60 g in 1 BOTTLE, PUMP	2023-10-30
Alembic	DAPSONE	dapsone	GEL;TOPICAL	215718	ANDA	Alembic Pharmaceuticals Limited	46708-663-90	1 BOTTLE, PUMP in 1 CARTON (46708-663-90) / 90 g in 1 BOTTLE, PUMP	2023-10-30
Alembic	DAPSONE	dapsone	GEL;TOPICAL	215718	ANDA	Alembic Pharmaceuticals Inc.	62332-663-30	1 BOTTLE, PUMP in 1 CARTON (62332-663-30) / 30 g in 1 BOTTLE, PUMP	2023-10-30
Alembic	DAPSONE	dapsone	GEL;TOPICAL	215718	ANDA	Alembic Pharmaceuticals Inc.	62332-663-60	1 BOTTLE, PUMP in 1 CARTON (62332-663-60) / 60 g in 1 BOTTLE, PUMP	2023-10-30

Dapsone Suppliers and Market Landscape

Last updated: February 19, 2026

This analysis details key suppliers of Dapsone, a sulfone antibiotic, and outlines the current market landscape. Information is critical for pharmaceutical companies engaged in Dapsone-based drug development, manufacturing, and investment.

Who Are the Primary Manufacturers and Suppliers of Dapsone?

The global supply of Dapsone is concentrated among a limited number of manufacturers, primarily located in India and China. These entities produce Active Pharmaceutical Ingredients (APIs) that are then used by formulators worldwide.

• Indian Manufacturers: India is a significant hub for Dapsone API production. Companies like Aarti Drugs Ltd., IOL Chemicals and Pharmaceuticals Ltd., and Shasun Pharmaceuticals Ltd. (now a part of Strides Pharma Science) have historically been key players.

  • Aarti Drugs Ltd.: A prominent pharmaceutical ingredient manufacturer, Aarti Drugs produces Dapsone as part of its broader API portfolio. Its manufacturing facilities adhere to cGMP standards and are subject to regulatory inspections by agencies such as the US FDA and EMA.
  • IOL Chemicals and Pharmaceuticals Ltd. (IOLCP): IOLCP manufactures Dapsone, focusing on quality and regulatory compliance. Their production capacity and adherence to international standards are critical factors for global pharmaceutical clients.
  • Strides Pharma Science Ltd. (formerly Shasun Pharmaceuticals): While Shasun was acquired by Strides, its API manufacturing capabilities, including Dapsone, remain a relevant part of the supply chain.

• Chinese Manufacturers: China also contributes substantially to the global Dapsone API supply. Companies such as Zhejiang NHU Co., Ltd. and Xiamen Kingdomway Group Company are known producers.

  • Zhejiang NHU Co., Ltd.: NHU is a large-scale manufacturer of APIs and nutritional products. Its Dapsone production serves both domestic and international markets, with an emphasis on large-volume supply.
  • Xiamen Kingdomway Group Company: Kingdomway is involved in the production of various pharmaceutical ingredients. Their role in the Dapsone market is tied to their chemical synthesis capabilities and global distribution network.

• Other Suppliers: While the majority of high-volume API production is based in Asia, some European and North American companies may act as distributors or specialized niche manufacturers, though they are less dominant in raw API supply.

What Are the Key Regulatory Considerations for Dapsone Suppliers?

Dapsone is a regulated pharmaceutical ingredient, and its suppliers must meet stringent quality and compliance standards. These include Good Manufacturing Practices (GMP), as well as specific requirements from national and international health authorities.

• Current Good Manufacturing Practices (cGMP): All API manufacturers must comply with cGMP guidelines. These regulations ensure that products are consistently produced and controlled according to quality standards. This involves detailed documentation, validated processes, and robust quality control systems.

  • US FDA: Manufacturers supplying to the US market must comply with US FDA cGMP regulations (21 CFR Parts 210 and 211). Inspections by the FDA are common for API facilities.
  • European Medicines Agency (EMA): For European markets, compliance with EU GMP is required. Manufacturers often seek Certificates of Suitability (CEP) from the European Directorate for the Quality of Medicines & HealthCare (EDQM) for their APIs.
  • Other Regulatory Bodies: Manufacturers also need to comply with the requirements of other national regulatory agencies, such as Japan's PMDA and Health Canada.

• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory authorities like the FDA. A DMF is a submission to regulatory authorities containing confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. This allows drug product manufacturers to reference the DMF in their own applications without having direct access to the proprietary information.

  • US FDA DMFs: A significant number of Dapsone DMFs exist, indicating active regulatory filings and a mature supply chain.
  • European EDQM CEPs: Certificates of Suitability are also common, facilitating the use of Dapsone APIs in European pharmaceutical products.

• Quality Standards and Specifications: Suppliers must meet pharmacopoeial standards, such as those outlined in the United States Pharmacopeia (USP) and the European Pharmacopoeia (Ph. Eur.). These monographs define the identity, purity, and assay requirements for Dapsone.

  • USP Dapsone Monograph: Specifies tests for identification, assay (typically by titration), related substances, and residual solvents.
  • Ph. Eur. Dapsone Monograph: Similar to USP, it details requirements for quality and purity.

What is the Market Outlook for Dapsone?

The market for Dapsone is driven by its established use in treating conditions such as leprosy and dermatitis herpetiformis. Emerging applications and research into new therapeutic uses could influence future demand.

• Therapeutic Applications:

  • Leprosy (Hansen's Disease): Dapsone remains a cornerstone in multidrug therapy for leprosy, a chronic infectious disease. The World Health Organization (WHO) recommends Dapsone as part of standard multidrug regimens.
  • Dermatitis Herpetiformis: This chronic autoimmune blistering skin disease is effectively managed with Dapsone.
  • Other Dermatological Conditions: Dapsone is also used off-label for conditions like acne vulgaris, psoriasis, and certain inflammatory dermatoses, although its use in these areas may be limited by side effects.
  • Pneumocystis Pneumonia (PCP) Prophylaxis: Dapsone is an alternative prophylactic agent for PCP in immunocompromised individuals, particularly those with HIV/AIDS or undergoing chemotherapy, especially when trimethoprim-sulfamethoxazole is contraindicated.

• Market Dynamics:

  • Generic Market: Dapsone is an established drug with generic availability, leading to price competition among manufacturers. The market is largely driven by cost-effectiveness and reliable supply.
  • Disease Prevalence: The prevalence of leprosy, though declining globally due to effective treatment, still sustains demand in endemic regions. Dermatitis herpetiformis affects a smaller but consistent patient population.
  • Research and Development: While Dapsone is an older drug, ongoing research into its anti-inflammatory properties and potential synergistic effects with other agents could open new therapeutic avenues. Studies explore its utility in conditions like bullous pemphigoid and even certain cancers, though these are primarily in early-stage research.

• Supply Chain Resilience: The concentration of manufacturing in specific geographic regions (India and China) presents a potential risk for supply chain disruptions. Geopolitical factors, regulatory changes, or unforeseen events impacting these regions can affect global availability and pricing. Pharmaceutical companies often mitigate this by diversifying their supplier base or maintaining strategic inventory levels.

• Pricing Trends: Dapsone API pricing is influenced by raw material costs, manufacturing efficiencies, regulatory compliance expenses, and the overall supply-demand balance. While generally considered an affordable API, significant fluctuations can occur based on global events impacting chemical production or logistics. Prices for bulk API can range from approximately $15 to $40 per kilogram, depending on purity, volume, and supplier.

What Are Potential Challenges and Opportunities for Dapsone Suppliers?

Suppliers face both headwinds and potential avenues for growth in the Dapsone market.

• Challenges:

  • Regulatory Scrutiny: Continuous adherence to evolving GMP standards and pharmacopoeial requirements necessitates ongoing investment in quality systems and compliance.
  • Competition: The generic nature of Dapsone leads to intense price competition, pressuring profit margins for API manufacturers.
  • Adverse Event Profile: Dapsone's known adverse effects, including methemoglobinemia and hemolytic anemia, particularly in individuals with G6PD deficiency, can limit its use in certain patient populations and research areas. This necessitates careful patient selection and monitoring.
  • Supply Chain Vulnerabilities: Reliance on a few key suppliers or regions for raw materials or manufacturing can expose the supply chain to risks.

• Opportunities:

  • Emerging Markets: Continued efforts to eradicate leprosy in endemic regions of Asia, Africa, and Latin America will sustain demand for Dapsone.
  • New Indications Research: Successful clinical development for novel uses of Dapsone, such as in inflammatory or autoimmune diseases beyond its current indications, could significantly expand market demand.
  • Quality and Reliability Differentiation: Suppliers who can consistently demonstrate superior quality, robust regulatory compliance, and reliable supply chains can command a premium and secure long-term contracts.
  • Vertical Integration: Companies involved in both API manufacturing and finished dosage form production can optimize their supply chains and potentially achieve better cost control.

Key Takeaways

The Dapsone API market is dominated by manufacturers in India and China, with Aarti Drugs Ltd., IOL Chemicals and Pharmaceuticals Ltd., and Zhejiang NHU Co., Ltd. being significant producers. Compliance with cGMP, FDA, and EMA regulations, supported by DMF filings and pharmacopoeial standards, is critical for supplier viability. The market is driven by Dapsone's established role in treating leprosy and dermatitis herpetiformis. While competition is high due to its generic status, potential growth exists through research into new indications and a focus on supply chain resilience and quality assurance.

Frequently Asked Questions

1. What is the typical lead time for procuring bulk Dapsone API from major suppliers? Lead times can vary based on supplier inventory, order volume, and current production schedules. Generally, lead times can range from 4 to 12 weeks for significant orders, with smaller quantities potentially available more rapidly.

2. Are there any known shortages of Dapsone API in the current market? As of the latest market intelligence, there are no widespread, persistent shortages of Dapsone API reported. However, localized or temporary supply constraints can occur due to specific manufacturing issues or logistical challenges.

3. Which Dapsone suppliers have the most recent US FDA inspection approvals? Specific FDA inspection outcomes are not publicly disclosed in real-time. Pharmaceutical companies typically conduct their own due diligence or rely on third-party audits to verify supplier compliance. Manufacturers' DMFs usually indicate a history of regulatory submissions and interactions.

4. What is the impact of patent expirations on Dapsone manufacturing? Dapsone is a well-established drug whose primary patents expired decades ago. This has allowed for widespread generic manufacturing, leading to the current competitive landscape where API production is focused on cost efficiency and regulatory adherence rather than new patent protection.

5. Does Dapsone have specific storage and handling requirements that suppliers must adhere to? Yes, Dapsone API should be stored in well-closed containers, protected from light, and at controlled room temperatures to maintain its stability and purity. Suppliers must follow these guidelines during storage and transportation to ensure the integrity of the API.

Citations

[1] U.S. Food & Drug Administration. (n.d.). Code of Federal Regulations Title 21 Part 210: Current Good Manufacturing Practice in Manufacturing, Processing, Packing, or Holding of Drugs; General. U.S. Government Publishing Office. [2] U.S. Food & Drug Administration. (n.d.). Code of Federal Regulations Title 21 Part 211: Current Good Manufacturing Practice for Finished Pharmaceuticals. U.S. Government Publishing Office. [3] European Medicines Agency. (n.d.). Good Manufacturing Practice. Retrieved from https://www.ema.europa.eu/en/human-regulatory/research-and-development/compliance-research-and-development/good-manufacturing-practice [4] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificates of Suitability to the monographs of the European Pharmacopoeia (CEP). Retrieved from https://www.edqm.eu/en/certificates-suitability-monographs-european-pharmacopoeia-cep [5] United States Pharmacopeial Convention. (n.d.). USP Monograph: Dapsone. Retrieved from USP-NF Online. [6] European Pharmacopoeia. (n.d.). Ph. Eur. Monograph: Dapsone. Retrieved from European Pharmacopoeia Online. [7] World Health Organization. (2020). Leprosy: Fact sheet. Retrieved from https://www.who.int/news-room/fact-sheets/detail/leprosy [8] Market Research Reports on Pharmaceutical APIs (various publishers, accessed for general market trends and pricing indicators).